ResMed| · Earnings release · 8-K Exhibit 99

For investors

For media

investorrelations@resmed.com

news@resmed.com

Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026

•

T1Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis

•

T2GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps

•

GAAP income from operations increased 17%; non-GAAP income from

operations up 18%

•

GAAP diluted earnings per share of $2.74; non-GAAP diluted earnings per

•

Operating cash flow of $554 million; $T3262 million returned to shareholders through share repurchases and

dividends

Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, April 30, 2026 – Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2026.

“Our third quarter results reflect the continued strength of our global business, driven by ongoing demand for our market-leading products and disciplined

execution of our strategy,” said Resmed’s Chairman and CEO, Mick Farrell.

“Year-over-year, we delivered 11% reported revenue growth, 290 basis

points of non-GAAP gross margin expansion, and 21% increase in earnings per share. These results highlight the momentum behind our strategy, and the continued progress we are making in shaping the future of

sleep health, breathing health, and healthcare in the home.

As we advance through the remainder of our fiscal year 2026, we remain focused on expanding access to

care globally, scaling our digital health capabilities, and delivering further strong, profitable growth.”

Financial Results and Operating Metrics

Unaudited; $ in millions, except for per share amounts

Three Months Ended

% Change

Constant

Currency(A)

Revenue

$

$

%

8

%

Gross margin

%

%

5

Non-GAAP gross margin (B)

%

%

5

Selling, general, and administrative expenses

Non-GAAP selling, general, and administrative expenses(B)

9

Research and development expenses

8

Income from operations

Non-GAAP income from operations (B)

Net income

9

Non-GAAP net income (B)

Diluted earnings per share

$

$

Non-GAAP diluted earnings per share (B)

$

$

Nine Months Ended

% Change

Constant

Currency(A)

Revenue

$

$

%

8

%

Gross margin

%

%

5

Non-GAAP gross margin (B)

%

%

5

Selling, general, and administrative expenses

Non-GAAP selling, general, and administrative expenses(B)

9

Research and development expenses

9

Income from operations

Non-GAAP income from operations (B)

Net income

Non-GAAP net income (B)

Diluted earnings per share

$

$

Non-GAAP diluted earnings per share (B)

$

$

(A)

In order to provide a framework for assessing how our underlying businesses performed, excluding the effect of foreign

currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the

current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar

measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

(B)

See the reconciliation of non-GAAP financial measures in the table at the end of

the press release.

Discussion of Third Quarter Results

All comparisons are to the prior year period unless otherwise noted

•

Revenue grew by 8 percent on a constant currency basis, driven by increased demand for our portfolio of sleep devices,

masks and accessories.

•

T4Revenue in the U.S., Canada, and Latin America, excluding Residential Care Software, grew by 9 percent.

•

Revenue in Europe, Asia, and other markets, excluding Residential Care Software, grew by 7 percent on a constant

currency basis.

•

Residential Care Software revenue increased by 4 percent on a constant currency basis.

•

Gross margin increased by 290 basis points primarily driven by component cost improvements and manufacturing and logistics

efficiencies, as well as a small positive impact from product mix and foreign currency movements. Non-GAAP gross margin increased by 290 basis points due to the same factors.

•

Selling, general, and administrative expenses increased by 11 percent on a constant currency basis. T5The increase in

SG&A expenses was mainly due to additional expenses associated with our VirtuOx acquisition, employee costs as well as marketing and technology investments. Additionally, we recorded acquisition and portfolio review related expenses of

$5.9 million reflecting costs associated with the evaluation of strategic transactions, including legal and professional fees for diligence and related consultations. SG&A expenses, excluding acquisition and portfolio review related

expenses, were 19.5 percent of revenue in the quarter, compared with 19.0 percent in the same period of the prior year.

•

Income from operations increased by 17 percent and non-GAAP income from

operations increased by 18 percent.

•

Net income for the quarter was $399 million and diluted earnings per share was$2.74. Non-GAAP net income increased by 20 percent to $417 million, and non-GAAP diluted earnings per share increased by 21 percent to

$2.86, predominantly attributable to strong sales growth and gross margin improvement.

•

Operating cash flow for the quarter was $554 million, compared to net income in the current quarter of

$399 million and non-GAAP net income of $417 million.

•

During the quarter, we paid $87 million in dividends to shareholders and repurchased 673,000 shares for consideration

of $175 million as part of our ongoing capital management.

Other Business and Operational Highlights

•

Unveiled findings from sixth annual Global Sleep Survey, drawing insights from 30,000 people across 13 countries; as sleep

awareness grows, so does the opportunity to turn intent into action.

•

Announced expansion of U.S. operations with new distribution center in Greenwood, Indiana, scheduled to begin operations in

2027 and expand Resmed’s U.S. presence while strengthening the company’s distribution capacity to better serve patients and providers across North America.

•

Launched the AirTouch F30i Comfort full face mask in the U.S. following its introduction in Australia and Canada, and

building on the launch of the AirTouch F30i Clear in the U.S.

Dividend program

The

Resmed board of directors today declared a quarterly cash dividend of $0.60 per share. The dividend will have a record date of May 14, 2026, payable on June 18, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s

common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the

record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be May 13, 2026, for common stockholders and for CDI holders. Resmed has received a waiver from

the ASX’s settlement operating rules, which will allow Resmed to defer processing conversions between its common stock and CDI registers from May 13, 2026, through May 14, 2026, inclusive.

Webcast details

Resmed will discuss its third quarter fiscal year

2026 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on Resmed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon

for the “Q3 2026 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone

replay of the conference call will be available approximately three hours after the webcast by dialing +1 877-660-6853 (U.S.) or+1 201-612-7415 (outside U.S.) and entering the passcode 13759381. The telephone replay will be available until May 14, 2026.

About Resmed

Resmed (NYSE: RMD, ASX: RMD) creates life-changing

health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. T6Our AI-powereddigital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better

sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.

Safe

harbor statement

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the

Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding Resmed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets

for its products, the integration of acquisitions, our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions of our business – are subject to risks and

uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in Resmed’s periodic reports on file with the U.S.

Securities & Exchange Commission. Resmed does not undertake to update its forward-looking statements.

– More –

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(Unaudited; $ in

thousands, except for per share amounts)

Three Months Ended

Nine Months Ended

Net revenue

$

$

$

$

Cost of sales

Amortization of acquired

intangibles (1)

Total cost of sales

$

$

$

$

Gross profit

$

$

$

$

Selling, general, and administrative

Acquisition and portfolio review related expenses(1)

—

—

Total selling, general, and administrative

Research and development

Amortization of acquired

intangibles (1)

Restructuring expenses (1)

—

—

—

Total operating expenses

$

$

$

$

Income from operations

$

$

$

$

Other income (expenses), net:

Interest (expense) income, net

$

$

$

$

)

Gain (loss) attributable to equity method investments

Gain (loss) on equity investments

)

)

)

)

Other, net

)

)

)

)

Total other income (expenses), net

)

)

Income before income taxes

$

$

$

$

Income taxes

Net income

$

$

$

$

Basic earnings per share

$

$

$

$

Diluted earnings per share

$

$

$

$

Non-GAAP diluted earnings per share (1)

$

$

$

$

Basic shares outstanding

Diluted shares outstanding

(1)

See the reconciliation of non-GAAP financial measures in the table at

the end of the press release.

– More –

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(Unaudited; $ in thousands)

Assets

Current assets:

Cash and cash equivalents

$

$

Accounts receivable, net

Inventories

Prepayments and other current assets

Total current assets

$

$

Non-current assets:

Property, plant, and equipment, net

$

$

Operatinglease right-of-use assets

Goodwill and other intangibles, net

Deferred income taxes andother non-current assets

Total non-current assets

$

$

Total assets

$

$

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable

$

$

Accrued expenses

Operating lease liabilities, current

Deferred revenue

Income taxes payable

Short-term debt

Total current liabilities

$

$

Non-current liabilities:

Deferred revenue

$

$

Deferred income taxes

Operating lease liabilities, non-current

Other long-term liabilities

Long-term debt

Total non-current liabilities

$

$

Total liabilities

$

$

Stockholders’ equity

Common stock

$

$

Additional paid-in capital

Retained earnings

Treasury stock

)

)

Accumulated other comprehensive income

)

)

Total stockholders’ equity

$

$

Total liabilities and stockholders’ equity

$

$

– More –

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited; $ in

thousands)

Three Months Ended

Nine Months Ended

Cash flows from operating activities:

Net income

$

$

$

$

Adjustment to reconcile net income to cash provided by operating activities:

Depreciation and amortization

Amortizationof right-of-use assets

Stock-based compensation costs

(Gain) loss attributable to equity method investments, net of dividends received

)

)

)

)

(Gain) loss on equity investments

Changes in operating assets and liabilities:

Accounts receivable, net

)

)

)

)

Inventories, net

)

Prepaid expenses, net deferred income taxes and other current assets

)

)

Accounts payable, accrued expenses, income taxes payable and other

Net cash provided by (used in) operating activities

$

$

$

$

Cash flows from investing activities:

Purchases of property, plant, and equipment

)

)

)

)

Patent registration and acquisition costs

)

)

)

)

Purchases of intangible assets

—

—

)

—

Business acquisitions, net of cash acquired

)

—

)

)

Purchases of investments

)

)

)

)

Proceeds from exits of investments

—

Proceeds (payments) on maturity of foreign currency contracts

)

Net cash provided by (used in) investing activities

$

)

$

)

$

)

$

)

Cash flows from financing activities:

Proceeds from issuance of common stock, net

Purchases of treasury stock

)

)

)

)

Taxes paid related to net share settlement of equity awards

)

)

)

)

Payments of business combination contingent consideration

—

—

—

)

Repayment of borrowings

—

—

)

)

Dividends paid

)

)

)

)

Net cash provided by (used in) financing activities

$

)

$

)

$

)

$

)

Effect of exchange rate changes on cash

$

$

$

$

)

Net increase (decrease) in cash and cash equivalents

Cash and cash equivalents at beginning of period

Cash and cash equivalents at end of period

$

$

$

$

– More –

RESMED INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial Measures

(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles and are

reconciled below:

Three Months Ended

Nine Months Ended

Revenue

$

$

$

$

GAAP cost of sales

$

$

$

$

Less: Amortization of acquired

intangibles (A)

)

)

)

)

Non-GAAP cost of sales

$

$

$

$

GAAP gross profit

$

$

$

$

GAAP gross margin

%

%

%

%

Non-GAAP gross profit

$

$

$

$

Non-GAAP gross margin

%

%

%

%

The measures “non-GAAP selling, general, and administrative expenses” and “non-GAAP selling, general, and administrative expenses as a percentage of revenues” exclude acquisition and portfolio review related expenses and are reconciled below:

Three Months Ended

Nine Months Ended

Revenue

$

$

$

$

GAAP selling, general, and administrative

Less: Acquisition and portfolio review related expenses (A)

)

—

)

—

Non-GAAP selling, general, and administrative

As a percentage of revenue:

GAAP selling, general, and administrative expenses

%

%

%

%

Non-GAAP selling, general, and administrative expenses

%

%

%

%

The measure “non-GAAP income from operations” is reconciled with GAAP

income from operations below:

Three Months Ended

Nine Months Ended

GAAP income from operations

$

$

$

$

Amortization of acquired intangibles—cost of

sales (A)

Amortization of acquired intangibles—operating expenses (A)

Restructuring (A)

—

—

—

Acquisition and portfolio review related expenses(A)

—

—

Non-GAAP income from operations

$

$

$

$

– More –

RESMED INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial Measures

(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted

earnings per share in the table below:

Three Months Ended

Nine Months Ended

GAAP net income

$

$

$

$

Amortization of acquired intangibles—cost of

sales (A)

Amortization of acquired intangibles—operating expenses (A)

Restructuring expenses (A)

—

—

—

Acquisition and portfolio review related

expenses (A)

—

—

Income tax effect of interest and penalties on income tax refunds (A)

—

)

—

)

Income tax effect on non-GAAP adjustments (A)

)

)

)

)

Non-GAAP net income (A)

$

$

$

$

GAAP diluted shares outstanding

GAAP diluted earnings per share

$

$

$

$

Non-GAAP diluted earnings per share (A)

$

$

$

$

(A)

Resmed adjusts for the impact of the amortization of acquired intangibles, restructuring expenses, and acquisition and

portfolio review related expenses from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.

Resmed believes that non-GAAP diluted earnings per share is an additional measure of performance that

investors can use to compare operating results between reporting periods. Resmed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current

period and in comparing it to past periods. Resmed believes this information provides investors better insight when evaluating Resmed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Likeall non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under

GAAP.

– More –

RESMED INC. AND SUBSIDIARIES

Revenue by Product and Region

(Unaudited; $ in millions, except for per

share amounts)

Three Months Ended

(A)

(A)

% Change

Constant

Currency(B)

U.S., Canada, and Latin America

Devices

$

$

6

%

Masks and other

Total U.S., Canada and Latin America

$

$

9

Combined Europe, Asia, and other markets

Devices

$

$

%

6

%

Masks and other

Total Combined Europe, Asia and other markets

$

$

7

Global revenue

Total Devices

$

$

9

%

6

%

Total Masks and other

Total Sleep and Breathing Health

$

$

8

Residential Care Software

6

4

Total

$

$

8

Nine Months Ended

(A)

(A)

%

Change

Constant

Currency(B)

U.S., Canada, and Latin America

Devices

$

$

7

%

Masks and other

Total U.S., Canada and Latin America

$

$

Combined Europe, Asia, and other markets

Devices

$

$

%

6

%

Masks and other

7

Total Combined Europe, Asia and other markets

$

$

6

Global revenue

Total Devices

$

$

9

%

7

%

Total Masks and other

Total Sleep and Breathing Health

$

$

9

Residential Care Software

6

4

Total

$

$

8

(A)

Totals and subtotals may not add due to rounding.

(B)

In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign

currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the

current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar

measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

– End –